NEW MJ NEWS

AbbVie to Host Third-Quarter 2022 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-third-quarter-2022-earnings-conference-call-301639218.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie (ABBV) to Present at the Bank of America Securities Healthcare Conference

AbbVie to Present at the Bank of America Securities Healthcare Conference AbbVie…

SNDL Inc. (SNDL) and Nova Cannabis Extend Outside Date for Closing of the Strategic Partnership

SNDL and Nova Cannabis Extend Outside Date for Closing of the Strategic…

$MJNA Celebrate 15 Year-Old Boy’s Free Access

Photo Release — Medical Marijuana, Inc. and HempMeds Brasil(TM) Celebrate 15 Year-Old…

AbbVie Inc. (ABBV) Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®)

AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3…